Allyson leverages her in-house experience to provide holistic counsel to publicly traded and late-stage private companies on corporate and securities law matters.
Allyson advises companies on SEC reporting and disclosure requirements, corporate governance, stock exchange requirements and proxy advisory firm policies. Allyson routinely represents issuers on a variety of transactions, with a focus on initial public offerings, follow-on offerings, private investments in public equity (PIPEs), registered direct offerings and mergers and acquisitions.
Before rejoining Mintz, Allyson was Senior Counsel, Corporate and Securities at a prominent tech company in New York, where she advised the board and senior management on a wide range of corporate and securities law matters.
Experience
Select Initial Public Offering Representations
- Viela Bio, Inc. in its $150 million initial public offering.
- NuCana plc. in its $114 million initial public offering.
- Quanterix Corporation in its $73.7 million initial public offering.
Select Follow-on Offering and Alternate Transaction Representations
- Intra-Cellular Therapies, Inc. in multiple offerings, including its $350 million follow-on offering, its $295 million follow-on offering, and its $150 million follow-on offering.
- Albireo Pharma, Inc. in multiple offerings, including its $160 million follow-on offering and its $65 million follow-on offering.
- Viela Bio, Inc. in multiple offerings, including its $170 million follow-on offering.
- Nucana plc. in multiple offerings, including its $70 million follow-on offering.
- J.P. Morgan, SVB Leerink, and Cowen in Acceleron Pharma Inc.’s $493 million follow-on offering.
- Goldman Sachs, Morgan Stanley, J.P. Morgan, and Cowen in GW Pharmaceuticals plc.’s $345 million follow-on offering.
- Goldman Sachs and Leerink Partners in a $50.5 million secondary offering of Achillion Pharmaceuticals, Inc.’s common stock by selling stockholder Johnson & Johnson Innovation-JJDC, Inc.
- Leerink Partners in ArQule, Inc.’s $65 million follow-on offering.
Select Mergers and Acquisitions Representations
- Albireo Pharma, Inc. in its reverse merger with Biodel Inc.
- F-star Therapeutics, Inc. in its reverse merger with Spring Bank Pharmaceuticals.
viewpoints
Reminder – T-1 Settlement Starts Today, Tuesday, May 28, 2024
May 28, 2024 | Alert | By Daniel T. Kajunski, Allyson Wilkinson
Starting today, Tuesday, May 28, 2024, the amendments to Securities Exchange Act Rule 15c6-1 take effect, shortening the settlement cycle for most broker-dealer securities transactions to the trade date plus one business day (T+1) from the trade date plus two business days (T+2). In this alert, we discuss the T+1 settlement cycle and best practices for issuers to mitigate compliance issues and reduce the risk of failed settlements.
News & Press
Mintz advised the underwriters in connection with Cogent Biosciences, Inc.’s concurrent public offerings of $345 million of common stock (the “Equity Offering”) and $230 million in aggregated principal amount of 1.625% convertible senior notes due 2031 (the “Convertible Notes Offering”).
Mintz Advises on MoonLake Immunotherapeutics’ $75 Million Offering
November 12, 2025
Mintz advised the underwriter in connection with a $75 million underwritten offering by MoonLake Immunotherapeutics of 7,142,857 Class A ordinary shares at an offering price of $10.50 per share. The aggregate gross proceeds to MoonLake Immunotherapeutics from this offering were approximately $75 million before deducting underwriting discounts and commissions and other offering expenses.
Mintz Advises on Benitec Biopharma’s $80 Million Follow-On Offering and Concurrent $20 Million Registered Direct Offering
November 12, 2025
Mintz advised the underwriters in connection with Benitec Biopharma’s follow-on public offering of 5,930,000 shares of common stock at a public offering price of $13.50 per share, and the placement agents in the concurrent registered direct offering of 1,481,481 shares of common stock at an offering price of $13.50 per share. The aggregate gross proceeds to Benitec Biopharma from these offerings were approximately $100 million before deducting underwriting discounts and commissions, placement agent fees, and other offering expenses. In addition, Benitec Biopharma granted the underwriters a 30-day option to purchase up to an additional 889,500 shares of its common stock at the public offering price.
Events & Speaking
Recognition & Awards
Massachusetts Super Lawyers Rising Star: Business/Corporate Transactions (2025)
Richard Mintz Scholarship Recipient
Boston College Law School’s Pro Bono Excellence Recognition
National Black Lawyers: Top 40 Under 40 (2022)
Massachusetts Lawyers Weekly: Excellence in the Law, Up & Coming Lawyer Award (2020)
Involvement
- Director, The Equity in Heart Transplant Project (2022 – present)
- Clerk, The Equity in Heart Transplant Project (2022 – 2023)
- Treasurer, Massachusetts Black Lawyers Association (2022 – 2023)
- Business Transactions Liaison, New Lawyers Steering Committee of the Boston Bar Association (2020 – 2021)
- Director, Boston College Law School Black Alumni Network (2019 – 2020)
Recent Insights
Mintz advised the underwriters in connection with Cogent Biosciences, Inc.’s concurrent public offerings of $345 million of common stock (the “Equity Offering”) and $230 million in aggregated principal amount of 1.625% convertible senior notes due 2031 (the “Convertible Notes Offering”).
Mintz advised the underwriter in connection with a $75 million underwritten offering by MoonLake Immunotherapeutics of 7,142,857 Class A ordinary shares at an offering price of $10.50 per share. The aggregate gross proceeds to MoonLake Immunotherapeutics from this offering were approximately $75 million before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with Benitec Biopharma’s follow-on public offering of 5,930,000 shares of common stock at a public offering price of $13.50 per share, and the placement agents in the concurrent registered direct offering of 1,481,481 shares of common stock at an offering price of $13.50 per share. The aggregate gross proceeds to Benitec Biopharma from these offerings were approximately $100 million before deducting underwriting discounts and commissions, placement agent fees, and other offering expenses. In addition, Benitec Biopharma granted the underwriters a 30-day option to purchase up to an additional 889,500 shares of its common stock at the public offering price.
